Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- 28 July 2011
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 306 (2), 171-179
- https://doi.org/10.1016/j.canlet.2011.03.002
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Trastuzumab in gastric cancerEuropean Journal of Cancer, 2010
- Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44The International Journal of Cell Cloning, 2009
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug ConjugateCancer Research, 2008
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology, 2008
- Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistanceMolecular Cancer Therapeutics, 2007
- Chemotherapy of advanced gastric cancerCancer Treatment Reviews, 2007
- Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancerNature Clinical Practice Oncology, 2006
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnnals of Oncology, 2005
- p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cellsOncogene, 2000
- Antimitotic Activity of the Potent Tumor Inhibitor MaytansineScience, 1975